AI Article Synopsis

  • Targeting TLR3 with polyI:C shows promise as an adjuvant in cancer immunotherapy, especially when combined with anti-PD-L1 treatment.
  • Although polyI:C induces inflammation and type I interferon production in dendritic cells (DCs), it paradoxically impairs CD8+ T cell activation, mainly due to increased PD-L1 expression.
  • The study reveals a novel mechanism where CD40 signaling enhances PD-L1 surface expression in polyI:C-treated DCs, reducing T cell contact and potentially limiting T cell activation, providing insights into improving cancer immunotherapy strategies.

Article Abstract

Targeting TLR3 through formulations of polyI:C is widely studied as an adjuvant in cancer immunotherapy. The efficacy of such targeting has been shown to increase in combination with anti-PD-L1 treatment. Nevertheless, the mechanistic details of the effect of polyI:C on DC maturation and the impact on T-DC interactions upon PD-L1 blockade is largely unknown. Here we found that although DC treatment with polyI:C induced a potent inflammatory response including the production of type I interferon, polyI:C treatment of DCs impaired activation of peptide specific CD8+ T cells mainly due to PD-L1. Interestingly, we found that PD-L1 trafficking to the cell surface is regulated in two waves in polyI:C-treated DCs. One induced upon overnight treatment and a second more rapid one, specific to polyI:C treatment, was induced upon CD40 signaling leading to a further increase in surface PD-L1 in DCs. The polyI:C-induced cell surface PD-L1 reduced the times of contact between DCs and T cells, potentially accounting for limited T cell activation. Our results reveal a novel CD40-dependent regulation of PD-L1 trafficking induced upon TLR3 signaling that dictates its inhibitory activity. These results provide a mechanistic framework to understand the efficacy of anti-PD-L1 cancer immunotherapy combined with TLR agonists.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135054PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0167057PLOS

Publication Analysis

Top Keywords

pd-l1 trafficking
12
cancer immunotherapy
8
polyic treatment
8
cell surface
8
surface pd-l1
8
pd-l1
7
polyic
5
treatment
5
tlr3-induced maturation
4
maturation murine
4

Similar Publications

Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model.

J Control Release

January 2025

Precision Medicine in Oncology (PrMiO), and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address:

The recent approval of pembrolizumab in recurrent or metastatic cervical cancer warrants further investigations into the usefulness of immunotherapies for more durable and less radical interventions. In this study, the targeting potential of anti-PD-L1-functionalized immunoliposomes was tested in a 3D in vitro cervical cancer-on-a-chip model. Immunolipsomes were synthesized and decorated externally with monovalent anti-PD-L1 Fab' fragments of commercially available atezolizumab.

View Article and Find Full Text PDF

Triple negative breast cancers often contain higher numbers of tumour-infiltrating lymphocytes compared with other breast cancer subtypes, with their number correlating with prolonged survival. Since little is known about tumour-infiltrating lymphocyte trafficking in triple negative breast cancers, we investigated the relationship between tumour-infiltrating lymphocytes and the vascular compartment to better understand the immune tumour microenvironment in this aggressive cancer type. We aimed to identify mechanisms and signaling pathways responsible for immune cell trafficking in triple negative breast cancers, specifically of basal type, that could potentially be manipulated to change such tumours from immune "cold" to "hot" thereby increasing the likelihood of successful immunotherapy in this challenging patient population.

View Article and Find Full Text PDF

Disrupting EDEM3-induced M2-like macrophage trafficking by glucose restriction overcomes resistance to PD-1/PD-L1 blockade.

Clin Transl Med

January 2025

Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

Background: Immunotherapy is beneficial for some colorectal cancer (CRC) patients, but immunosuppressive networks limit its effectiveness. Cancer-associatedfibroblasts (CAFs) are significant in immune escape and resistance toimmunotherapy, emphasizing the urgent need for new treatment strategies.

Methods: Flow cytometric, Western blotting, proteomics analysis, analysis of public database data, genetically modified cell line models, T cell coculture, crystal violetstaining, ELISA, metabonomic and clinical tumour samples were conducted to assess the role of EDEM3 in immune escape and itsmolecular mechanisms.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma (GBM) is a highly aggressive brain cancer with very low survival rates, and laser interstitial thermal therapy (LITT) has emerged as a promising surgical option to reduce tumor burden and modulate immune responses.
  • The study investigated how thermal therapy and radiation affect the immune checkpoint PD-L1 in U87 GBM cells, particularly focusing on the differences between IDH-mutant and IDH-wildtype cells.
  • Results indicated that thermal therapy effectively killed GBM cells in a temperature-dependent manner, especially at higher temperatures, and notably reduced PD-L1 levels in U87 cells, which correlated with increased expression of a specific mitochondrial enzyme linked to iron metabolism.
View Article and Find Full Text PDF

Dendritic cells (DCs) orchestrate both immune activation and immune tolerance in multiple sclerosis (MS). Manipulating the phenotypes and functions of DCs to boost their tolerogenic potential is an appealing strategy for treating MS and its animal model experimental autoimmune encephalomyelitis (EAE). Programmed cell death 1 (PD-1) delivers the immunoinhibitory signals by interacting with PD-1 ligand 1 (PD-L1), which plays a critical role in maintaining immune tolerance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!